Pharmaceuticals

Lundbeck and Adcock Ingram strategic collaboration

Lundbeck South Africa MD, Ben Christen and Adcock Ingram CEO, Dr Jonathan Louw

Lundbeck, specialists in Central Nervous System (CNS) disorders, and Adcock Ingram, South Africa's second largest pharmaceutical company, on 19 November announced a five-year strategic collaboration to co-promote and distribute Lundbeck’s products. The collaboration is valued at R77 million per annum.

The key objective of the partnership is to capitalise on synergies that exist between the two organisations, namely Lundbeck’s CNS expertise and reputation in psychiatry and Adcock Ingram’s critical mass and distribution capabilities. The collaboration will bolster Adcock Ingram’s CNS product offering. Utilising Adcock Ingram’s large specialist, GP and pharmacy footprint, access to these products by prescribers and patients will be maximised.

Lundbeck has entered into collaboration with Adcock Ingram to co-promote and/or distribute the following CNS products: Cipralex – escitalopram; Cipramil – citalopram; Ebixa – memantine; Fluanxol Depot & Tablets – flupenthixol; Clopixol Depot, Tablets & Acuphase – zuclopenthixol; and Azilect – rasagiline.

Lundbeck is a global Denmark-based pharmaceutical company committed to improving the quality of life for people suffering from brain disorders. The company has been engaged in the research, development, production, marketing and sale of pharmaceuticals across the world for more than 50 years.

Image caption: Lundbeck South Africa MD, Ben Christen and Adcock Ingram CEO, Dr Jonathan Louw

Aspen breaks ground with another new choice brand

Box1 Eng-165

Pharmaceutical company Aspen has launched another choice brand, Enze-Lact capsules and drops, which is good news to those who have difficulty digesting lactose-containing milk or food products. The symptoms of lactose intolerance include diarrhoea, bloating, flatulence and abdominal pain¹.

Cold-chain storage critical to pharma’s future

Cold-chain-storage-critical-to-pharmas-futureAs temperature-sensitive drugs become more prevalent, pharmaceutical companies are increasing reliance, and spending, on cold-chain storage, according to a report by GBI Research.

Supporting growth through technology

Supporting-growth-through-technologyA new software solution is being used to manage production and inventory costs in the pharmaceutical industry.

CW Pharmaceuticals was established in the late 90’s as a small manufacturing entity with the sole purpose of developing and manufacturing Placecol skin care products. By implementing a meticulous approach to quality and service, the company grew, and started investing in suitable equipment and well-trained staff to enable it to compete in the contract manufacturing arena and expanded business operations to support the growing production facility.

Would you like to receive our FREE e-newsletter?

* indicates required
Close